Advanced Delivery Platforms for Base Editing In Vivo
用于体内碱基编辑的先进交付平台
基本信息
- 批准号:10682172
- 负责人:
- 金额:$ 58.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AdenineAdverse effectsAllelesAmyotrophic Lateral SclerosisCLN3 geneCRISPR/Cas technologyCentral Nervous SystemCentral Nervous System DiseasesClinicalClustered Regularly Interspaced Short Palindromic RepeatsCytidineDNA Sequence AlterationDeaminaseDendritic CellsDeoxyribonucleasesDependovirusDevelopmentDinucleoside PhosphatesDiseaseDisease modelEffectivenessEndowmentExonsExtrahepaticGenesGenetic DiseasesGoalsHepatic TissueHepatocyteHepatotoxicityImmune responseImmunityInterphase CellKnowledgeLiverMammalian CellMicroRNAsModalityMusMutagenesisMutateMutationNucleotidesPatientsPharmaceutical PreparationsRNARNA SplicingRepressionResearchRiskSafetySiteSpecificitySpielmeyer-Vogt DiseaseSpinal GangliaSystemTechnologyTestingTherapeuticTissuesToxic effectadverse outcomebase editingbase editorcell typeclinical practicedelivery vehicledensitydisease-causing mutationexon skipping therapygenome editinghumanized mouseimmunogenicityimprovedin vivoknockout genemouse modelmutantnext generationnovelpreventprime editingrepairedsuperoxide dismutase 1therapeutic genome editingvector
项目摘要
Project Summary
The Cas9 platform has enabled genome editing, base editing (BE), and prime editing to induce gene
knockouts as well as tailor-made sequence alterations. CRISPR-Cas9 systems have the potential to similarly
revolutionize clinical practice through precise editing of disease loci. We have developed Nme2Cas9 as an
editing platform with (1) compact size, facilitating single adeno-associated virus (AAV) delivery; (2) a
dinucleotide (N4CC) protospacer-adjacent motif (PAM) that affords high target site density; and (3) exceptional
accuracy. More recently, we developed Nme2Cas9 adenine base editor (ABE) systems as among the first to
be validated in vivo for single-AAV delivery. AAV is a potent editing delivery modality in vivo, especially in
extrahepatic tissues such as the central nervous system (CNS). Nonetheless, the therapeutic promise of base
editing systems will hinge upon improving editing efficiency, limiting bystander edits (or their consequences),
maximizing PAM-dependent targeting scope, and minimizing immunogenicity, toxicity, and prolonged
deaminase expression (which can compromise editing efficiency and lead to safety risks such as hepatotoxicity
and the accumulation of unwanted edits). Here we propose to capitalize on our establishment of single-vector
Nme2-ABE systems to develop novel base editing capabilities with increased effectiveness, targeting scope,
utility, and safety, and to validate these systems in the treatment of CNS disease models in mice. The goals of
this proposal are (1) to develop next-generation, single-AAV, deaminase-inlaid Nme2-ABEs and guides with
increased efficiency, a single-nucleotide PAM, and greater control over bystander editing; (2) to use next-
generation, single-AAV Nme2-ABE systems for therapeutic editing of disease genes in the CNS of mouse
models of amyotrophic lateral sclerosis and Batten disease; and (3) to develop systems that use repression by
endogenous microRNAs and drug-dependent splicing systems to enhance the safety of AAV-delivered Nme2-
ABE in vivo. These safety enhancements will reduce anti-Nme2-ABE immune responses, ameliorate potential
toxic effects on the liver and on specific CNS cell types, and limit the off-target mutagenesis that can arise from
sustained expression of the editing machinery. Successful completion of these aims will provide invaluable
enhancements to the delivery, efficacy, and specificity of in vivo genome editing.
项目摘要
Cas9平台使基因组编辑、碱基编辑(BE)和引物编辑能够诱导基因表达。
敲除以及量身定制的序列改变。CRISPR-Cas9系统具有类似的潜力,
通过精确编辑疾病位点来彻底改变临床实践。我们已经开发了Nme 2Cas 9作为一种
编辑平台,其具有(1)紧凑的尺寸,促进单个腺相关病毒(AAV)递送;(2)
二核苷酸(N4 CC)原型间隔区邻近基序(PAM),其提供高靶位点密度;和(3)特殊的
精度最近,我们开发了Nme 2Cas 9腺嘌呤碱基编辑器(ABE)系统,作为第一批
可以在体内验证单AAV递送。AAV是一种有效的体内编辑递送方式,特别是在哺乳动物中。
肝外组织如中枢神经系统(CNS)。尽管如此,基地的治疗前景
编辑系统将取决于提高编辑效率,限制旁观者编辑(或其后果),
最大化PAM依赖性靶向范围,并最小化免疫原性、毒性和延长
脱氨酶表达(其可损害编辑效率并导致安全性风险,例如肝毒性
以及不需要的编辑的积累)。在这里,我们建议利用我们建立的单矢量
Nme 2-ABE系统开发新的碱基编辑能力,具有更高的有效性,靶向范围,
实用性和安全性,并验证这些系统在治疗小鼠CNS疾病模型中的作用。的目标
该建议是(1)开发下一代、单AAV、脱氨酶镶嵌的Nme 2-ABE和具有以下特征的指南:
提高效率,单核苷酸PAM,以及对旁观者编辑的更大控制;(2)使用下一个-
用于小鼠CNS中疾病基因的治疗性编辑的单AAV Nme 2-ABE系统
肌萎缩性侧索硬化症和Batten病模型;以及(3)开发通过以下方式使用抑制的系统:
内源性microRNA和药物依赖性剪接系统,以增强AAV递送的Nme 2-
体内ABE。这些安全性增强将减少抗Nme 2-ABE免疫应答,改善潜在的
对肝脏和特定CNS细胞类型的毒性作用,并限制可能由
编辑机器的持续表达。这些目标的成功实现将提供宝贵的
增强体内基因组编辑的递送、功效和特异性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIK J. SONTHEIMER其他文献
ERIK J. SONTHEIMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIK J. SONTHEIMER', 18)}}的其他基金
Enhancing Genome Editing Technology with Natural Cas9 Inhibitors
利用天然 Cas9 抑制剂增强基因组编辑技术
- 批准号:
10092186 - 财政年份:2018
- 资助金额:
$ 58.37万 - 项目类别:
Engineered Cas9 Nucleases with Single-Genomic-Site Precision for CYBB Correction
用于 CYBB 校正的具有单基因组位点精度的工程化 Cas9 核酸酶
- 批准号:
9272917 - 财政年份:2016
- 资助金额:
$ 58.37万 - 项目类别:
Center for 3D Structure and Physics of the Genome
基因组 3D 结构和物理中心
- 批准号:
9021492 - 财政年份:2015
- 资助金额:
$ 58.37万 - 项目类别:
Mechanisms of Sequence-Based Resistance to Viruses and Plasmids in Eubacteria
真细菌基于序列的病毒和质粒抗性机制
- 批准号:
7748988 - 财政年份:2008
- 资助金额:
$ 58.37万 - 项目类别:
Mechanisms of Sequence-Based Resistance to Viruses and Plasmids in Eubacteria
真细菌基于序列的病毒和质粒抗性机制
- 批准号:
7600253 - 财政年份:2008
- 资助金额:
$ 58.37万 - 项目类别:
Improvement of RNAi efficacy by blocking RNAi inhibitors
通过阻断 RNAi 抑制剂提高 RNAi 功效
- 批准号:
7109912 - 财政年份:2006
- 资助金额:
$ 58.37万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 58.37万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 58.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 58.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 58.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 58.37万 - 项目类别:
Discovery Grants Program - Individual